Chairman and CEO
Rainier Therapeutics
Scott Myers has more than 20 years of biopharmaceutical industry experience in product commercialization and corporate transactions. He is currently the Chairman, President and CEO of Rainier Therapeutics, a private oncology company focused on bladder cancer. Prior to Rainier, Scott was CEO, President and a Director of Seattle-based Cascadian Therapeutics, a publicly-traded oncology company, until it was acquired by Seattle Genetics in March of 2018. Prior to Cascadian, he was CEO of Aerocrine AB, a medical device company based in Stockholm, Sweden, and Morrisville, NC, until it was acquired by Circassia, PLC in 2015. Prior to Aerocrine, Scott held senior commercial operations, general management and information management positions for UCB SA, a Belgium based biopharmaceutical company, and Johnson & Johnson. He is currently a Director of Harpoon Therapeutics (HARP), a public, clinical-stage immuno-oncology company. Scott earned his BA in biology from Northwestern University and his MBA from The University of Chicago Booth School of Business.